Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Stock Information for Cabaletta Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cabaletta Bio Inc.

Cabaletta Bio Announces Pricing of Public Offering of Securities
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle(TM) Platform
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.